# US 2022/0106609 A1 · Paravoviral vectors and methods of making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0106609 A1
- Document ID: US20220106609A1
- Status: Published application
- Kind: A1
- Application number: 17/310,424
- Filed: 2020-12-16
- Published: 2022-04-07
- Earliest claimed: 2019-12-17
- Assignees: Nikegen Limited
- Applicants: Nikegen, LLC
- Inventors: Weidong XIAO; Xiangping YU
- Web page: https://patentgrep.com/patent/US20220106609A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A recombination parvovirus vector that comprises a parvovirus capsid and a double-stranded vector genome having a sense-strand and an antisense-strand. The sense-strand comprises in the 5′ to 3′ direction: a parvovirus terminal repeat at the 5′ end a coding sequence of a gene of interest (GOI); and a parvovirus terminal repeat at the 3′ end. The vector genome further comprises a RNA destabilization/destruction domain (RDDD).

## Claims

### Claim 1

A parvovirus vector comprising:
a parvovirus capsid; and
a double-stranded vector genome comprising a sense-strand and an antisense-strand,
wherein the sense-strand comprises in the 5′ to 3′ direction:
a parvovirus terminal repeat at the 5′ end;
a coding sequence of a gene of interest (GOI); and
a parvovirus terminal repeat at the 3′ end,
wherein the vector genome further comprises a RNA destabilization/destruction domain (RDDD).

### Claim 2 (depends on 1)

The parvovirus vector of claim 1, wherein the RDDD is located in the antisense-strand.

### Claim 3 (depends on 1)

The parvovirus vector of claim 1, wherein the RDDD is located in an intron of the GOI in a reverse orientation.

### Claim 4 (depends on 1)

The parvovirus vector of claim 1, wherein the parvovirus vector is an AAV vector.

### Claim 5 (depends on 1, 2, 3, 4)

The parvovirus vector of any one of claims 1-4, wherein the RDDD comprises a microRMA.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The parvovirus vector of any one of claims 1 to 5, wherein the RDDD comprises SEQ ID NO:1 and/or SEQ ID NO:3.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The parvovirus vector of any one of claims 1 to 6, wherein the RDDD comprises two or more copies of SEQ ID NO:1 and/or two or more copies of SEQ ID NO:3.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The parvovirus vector of any one of claims 1 to 7, wherein the RDDD comprises the nucleotide sequence selected from the group consisting of SEQ ID NOS: 2, 4, 5, 6 and 7.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The parvovirus vector of any one of claims 1-9, further comprising a second RDDD.

### Claim 10 (depends on 9)

The parvovirus vector of claim 9, wherein the second RDDD comprises SEQ ID NO:8.

### Claim 11 (depends on 1, 2, 3, 4)

The parvovirus vector of any one of claims 1-4, wherein the RDDD comprises a ribozyme.

### Claim 12 (depends on 11)

The parvovirus vector of claim 11, wherein the ribozyme comprises SEQ ID NO:9.

### Claim 13

A method for improving production yield of a recombinant parvovirus, comprising the steps of:
inserting a RNA destabilization/destruction domain (RDDD) into the recombinant parvovirus,
wherein the recombinant parvovirus comprises:
a parvovirus capsid; and
a double-stranded viral genome comprising a sense-strand and an antisense-strand, wherein the sense-strand comprises in the 5′ to 3′ direction:
a parvovirus terminal repeat at the 5′ end;
a coding sequence of a gene of interest (GOI); and
a parvovirus terminal repeat at the 3′ end,
wherein the RDDD is inserted into the viral genome.

### Claim 14 (depends on 13)

The method of claim 13, wherein the RDDD is located in the antisense-strand of the viral genome

### Claim 15 (depends on 13)

The method of claim 13, wherein the RDDD is located in an intron of the GOI in a reverse orientation.
